uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Alternative names
Publications (10 of 67) Show all publications
Pirttilä, K., Pierre, P. V., Haglöf, J., Engskog, M., Hedeland, M., Laurell, G., . . . Pettersson, C. (2019). An LCMS-based untargeted metabolomics protocol for cochlear perilymph: highlighting metabolic effects of hydrogen gas on the inner ear of noise exposed Guinea pigs. Metabolomics, 15(10), Article ID 138.
Open this publication in new window or tab >>An LCMS-based untargeted metabolomics protocol for cochlear perilymph: highlighting metabolic effects of hydrogen gas on the inner ear of noise exposed Guinea pigs
Show others...
2019 (English)In: Metabolomics, ISSN 1573-3882, E-ISSN 1573-3890, Vol. 15, no 10, article id 138Article in journal (Refereed) Published
Abstract [en]

Introduction

Noise-induced hearing loss (NIHL) is an increasing problem in society and accounts for a third of all cases of acquired hearing loss. NIHL is caused by formation of reactive oxygen species (ROS) in the cochlea causing oxidative stress. Hydrogen gas (H-2) can alleviate the damage caused by oxidative stress and can be easily administered through inhalation.

Objectives

To present a protocol for untargeted metabolomics of guinea pig perilymph and investigate the effect of H-2 administration on the perilymph metabolome of noise exposed guinea pigs.

Methods

The left ear of guinea pigs were exposed to hazardous impulse noise only (Noise, n = 10), noise and H-2 (Noise + H2, n = 10), only H-2 (H2, n = 4), or untreated (Control, n = 2). Scala tympani perilymph was sampled from the cochlea of both ears. The polar component of the perilymph metabolome was analyzed using a HILIC-UHPLC-Q-TOF-MS-based untargeted metabolomics protocol. Multivariate data analysis (MVDA) was performed separately for the exposed- and unexposed ear.

Results

MVDA allowed separation of groups Noise and Noise + H2 in both the exposed and unexposed ear and yielded 15 metabolites with differentiating relative abundances. Seven were found in both exposed and unexposed ear data and included two osmoprotectants. Eight metabolites were unique to the unexposed ear and included a number of short-chain acylcarnitines.

Conclusions

A HILIC-UHPLC-Q-TOF-MS-based protocol for untargeted metabolomics of perilymph is presented and shown to be fit-for-purpose. We found a clear difference in the perilymph metabolome of noise exposed guinea pigs with and without H-2 treatment.

Keywords
Metabolomics, NIHL, In vivo, Noise-induced hearing loss, LCMS, Perilymph
National Category
Otorhinolaryngology
Identifiers
urn:nbn:se:uu:diva-396660 (URN)10.1007/s11306-019-1595-1 (DOI)000488961300002 ()31587113 (PubMedID)
Available from: 2019-11-12 Created: 2019-11-12 Last updated: 2019-11-12Bibliographically approved
Einarsson, S., Laurell, G. & Ehrsson, Y. T. (2019). Experiences and coping strategies related to food and eating up to two years after the termination of treatment in patients with head and neck cancer. European Journal of Cancer Care, 28(2), Article ID e12964.
Open this publication in new window or tab >>Experiences and coping strategies related to food and eating up to two years after the termination of treatment in patients with head and neck cancer
2019 (English)In: European Journal of Cancer Care, ISSN 0961-5423, E-ISSN 1365-2354, Vol. 28, no 2, article id e12964Article in journal (Refereed) Published
Abstract [en]

The purpose was to describe how patients with head and neck cancer experience and cope with difficulties related to food and eating up to two years after the termination of treatment. One hundred and thirty-five patients were followed with thematically structured interviews. The patients' responses of nutritional issues were categorised using similarities and differences technique. In the analysis, six categories emerged describing the process of eating and drinking from the end of treatment up to two years after treatment: The constant battle-eating and drinking over time, Food alterations and nutritional support-both pros and cons, Standing aside and not joining in when eating together with others, Finding ways to cope and to make the new a part of everyday life, Relationships and social support-hindrances and facilitators, and Longing for "normality." Results imply that patients struggle with physiological, psychological and social aspects related to food and eating, and use coping mechanisms to facilitate their eating problems. The best practice for rehabilitation and follow-up must be established in order to meet the multifaceted needs of head and neck cancer survivors.

Place, publisher, year, edition, pages
WILEY, 2019
Keywords
cancer, experiences, head and neck, nutrition, radiotherapy
National Category
Nursing
Identifiers
urn:nbn:se:uu:diva-380477 (URN)10.1111/ecc.12964 (DOI)000461076700005 ()30444049 (PubMedID)
Funder
Swedish Cancer Society
Available from: 2019-04-15 Created: 2019-04-15 Last updated: 2019-04-15Bibliographically approved
Lindell Jonsson, E., Erngren, I., Engskog, M., Haglöf, J., Arvidsson, T., Hedeland, M., . . . Nestor, M. (2019). Exploring Radiation Response in Two Head and Neck Squamous Carcinoma Cell Lines Through Metabolic Profiling. Frontiers in Oncology, 9, Article ID 825.
Open this publication in new window or tab >>Exploring Radiation Response in Two Head and Neck Squamous Carcinoma Cell Lines Through Metabolic Profiling
Show others...
2019 (English)In: Frontiers in Oncology, ISSN 2234-943X, E-ISSN 2234-943X, Vol. 9, article id 825Article in journal (Refereed) Published
Abstract [en]

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common form of cancer worldwide. Radiotherapy, with or without surgery, represents the major approach to curative treatment. However, not all tumors are equally sensitive to irradiation. It is therefore of interest to apply newer system biology approaches (e.g., metabolic profiling) in squamous cancer cells with different radiosensitivities in order to provide new insights on the mechanisms of radiation response. In this study, two cultured HNSCC cell lines from the same donor, UM-SCC-74A and UM-SCC-74B, were first genotyped using Short Tandem Repeat (STR), and assessed for radiation response by the means of clonogenic survival and growth inhibition assays. Thereafter, cells were cultured, irradiated and collected for subsequent metabolic profiling analyses using liquid chromatography-mass spectrometry (LC-MS). STR verified the similarity of UM-SCC-74A and UM-SCC-74B cells, and three independent assays proved UM-SCC-74B to be clearly more radioresistant than UM-SCC-74A. The LC-MS metabolic profiling demonstrated significant differences in the intracellular metabolome of the two cell lines before irradiation, as well as significant alterations after irradiation. The most important differences between the two cell lines before irradiation were connected to nicotinic acid and nicotinamide metabolism and purine metabolism. In the more radiosensitive UM-SCC-74A cells, the most significant alterations after irradiation were linked to tryptophan metabolism. In the more radioresistant UM-SCC-74B cells, the major alterations after irradiation were connected to nicotinic acid and nicotinamide metabolism, purine metabolism, the methionine cycle as well as the serine, and glycine metabolism. The data suggest that the more radioresistant cell line UM-SCC-74B altered the metabolism to control redox-status, manage DNA-repair, and change DNA methylation after irradiation. This provides new insights on the mechanisms of radiation response, which may aid future identification of biomarkers associated with radioresistance of cancer cells.

Keywords
radioresistance, radiosensitivity, metabolomics, mass spectrometry, redox status
National Category
Otorhinolaryngology Pharmaceutical Sciences Analytical Chemistry
Identifiers
urn:nbn:se:uu:diva-393266 (URN)10.3389/fonc.2019.00825 (DOI)000483315200001 ()31544064 (PubMedID)
Funder
Swedish Cancer Society, CAN 2018/494Swedish Cancer Society, CAN 2015/1080Swedish Cancer Society, CAN 2015/385Swedish Research Council, 201330876-104113-30
Note

De 2 första författarna delar förstaförfattarskapet.

Available from: 2019-09-18 Created: 2019-09-18 Last updated: 2019-12-09Bibliographically approved
Holm, A., Schindele, A., Allard, A., Eriksson, I., Sandström, K., Laurell, G., . . . Olofsson, K. (2019). Mapping of human papilloma virus, p16, and epstein-barr virus in non-malignant tonsillar disease. LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY, 4(3), 285-291
Open this publication in new window or tab >>Mapping of human papilloma virus, p16, and epstein-barr virus in non-malignant tonsillar disease
Show others...
2019 (English)In: LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY, ISSN 2378-8038, Vol. 4, no 3, p. 285-291Article in journal (Refereed) Published
Abstract [en]

Objectives Due to their location in the entrance of the aero-digestive tract, tonsils are steadily exposed to viruses. Human papilloma virus (HPV) and Epstein-Barr virus (EBV) are two potentially oncogenic viruses that tonsils encounter. The incidence of HPV positive tonsillar cancer is on the rise and it is unknown when infection with HPV occurs. Aim To investigate if tonsils are infected with HPV and EBV, to study the co-expression of HPV and its surrogate marker p16, and to evaluate the number of EBV positive cells in benign tonsillar disease. Materials and Methods Tonsils from 40 patients in a university hospital were removed due to hypertrophy, chronic or recurrent infection. These were analyzed for presence of HPV, its surrogate marker p16, and EBV. HPV was studied using PapilloCheck (a PCR method), while p16 was identified in epithelial and lymphoid tissue with immunohistochemistry and EBV using EBER-ISH (Epstein-Barr encoding region-in situ hybridization). Results HPV was not detected, and p16 was present at low numbers in all epithelial samples as well as in 92.5% of the lymphoid tonsillar samples. At least one EBER-positive cell was seen in 65% of cases. Larger numbers of EBER-expressing cells were only seen in two cases. Conclusion These findings demonstrate that EBV and HPV infect tonsils independently, but further studies are warranted to confirm their infectious relationship.

Place, publisher, year, edition, pages
WILEY, 2019
Keywords
Human papillomavirus, Epstein-Barr virus, non-malignant tonsillar disease, EBER-ISH, PapilloCheck, immunohistochemistry
National Category
Microbiology in the medical area Otorhinolaryngology
Identifiers
urn:nbn:se:uu:diva-390027 (URN)10.1002/lio2.260 (DOI)000471907200002 ()31236460 (PubMedID)
Funder
Västerbotten County Council
Available from: 2019-08-08 Created: 2019-08-08 Last updated: 2019-08-08Bibliographically approved
Pierre, P. V., Fransson, A., Kisiel, M. A., Damberg, P., Aski, S. N., Andersson, M., . . . Laurell, G. (2019). Middle Ear Administration of a Particulate Chitosan Gel in an in vivo Model of Cisplatin Ototoxicity. Frontiers in Cellular Neuroscience, 13, Article ID 268.
Open this publication in new window or tab >>Middle Ear Administration of a Particulate Chitosan Gel in an in vivo Model of Cisplatin Ototoxicity
Show others...
2019 (English)In: Frontiers in Cellular Neuroscience, ISSN 1662-5102, E-ISSN 1662-5102, Vol. 13, article id 268Article in journal (Refereed) Published
Abstract [en]

Background: Middle ear (intratympanic, IT) administration is a promising therapeutic method as it offers the possibility of achieving high inner ear drug concentrations with low systemic levels, thus minimizing the risk of systemic side effects and drug-drug interactions. Premature elimination through the Eustachian tube may be reduced by stabilizing drug solutions with a hydrogel, but this raises the secondary issue of conductive hearing loss. Aim: This study aimed to investigate the properties of a chitosan-based particulate hydrogel formulation when used as a drug carrier for IT administration in an in vivo model of ototoxicity. Materials and Methods: Two particulate chitosan-based IT delivery systems, Thio-25 and Thio-40, were investigated in albino guinea pigs (n = 94). Both contained the hearing protecting drug candidate sodium thiosulfate with different concentrations of chitosan gel particles (25% vs. 40%). The safety of the two systems was explored in vivo. The most promising system was then tested in guinea pigs subjected to a single intravenous injection with the anticancer drug cisplatin (8 mg/kg b.w.), which has ototoxic side effects. Hearing status was evaluated with acoustically evoked frequency-specific auditory brainstem response (ABR) and hair cell counting. Finally, in vivo magnetic resonance imaging was used to study the distribution and elimination of the chitosan-based system from the middle ear cavity in comparison to a hyaluronan-based system. Results: Both chitosan-based IT delivery systems caused ABR threshold elevations (p < 0.05) that remained after 10 days (p < 0.05) without evidence of hair cell loss, although the elevation induced by Thio-25 was significantly lower than for Thio-40 (p < 0.05). Thio-25 significantly reduced cisplatin-induced ABR threshold elevations (p < 0.05) and outer hair cell loss (p < 0.05). IT injection of the chitosan- and hyaluronan-based systems filled up most of the middle ear space. There were no significant differences between the systems in terms of distribution and elimination. Conclusion: Particulate chitosan is a promising drug carrier for IT administration. Future studies should assess whether the physical properties of this technique allow for a smaller injection volume that would reduce conductive hearing loss.

Place, publisher, year, edition, pages
FRONTIERS MEDIA SA, 2019
Keywords
auditory brainstem response, particulate chitosan, cisplatin, hair cell, hearing loss, intratympanic administration, magnetic resonance imaging, sodium thiosulfate
National Category
Otorhinolaryngology
Identifiers
urn:nbn:se:uu:diva-390821 (URN)10.3389/fncel.2019.00268 (DOI)000473162000001 ()31293387 (PubMedID)
Funder
Vinnova, 2015-00845
Available from: 2019-08-15 Created: 2019-08-15 Last updated: 2019-08-15Bibliographically approved
Laurell, G. (2019). Pharmacological intervention in the field of ototoxicity. Paper presented at 55th Inner Ear Biology Workshop, SEP 06-08, 2018, Berlin, GERMANY. HNO (Berlin. Print), 67(6), 434-439
Open this publication in new window or tab >>Pharmacological intervention in the field of ototoxicity
2019 (English)In: HNO (Berlin. Print), ISSN 0017-6192, E-ISSN 1433-0458, Vol. 67, no 6, p. 434-439Article in journal (Refereed) Published
Abstract [en]

Modern research on ototoxicity goes back to the 1940s, when streptomycin was introduced into clinical practice. Today, aminoglycoside antibiotics and platinum-based chemotherapy, mainly cisplatin, are the most important drugs that damage the inner ear and cause hearing loss. The mode of drug administration as well as drug characteristics influence the likelihood that adequate monitoring of drug pharmacokinetics can be performed. It is not possible to predict the individual risk of treatment with an ototoxic drug, but identification of high-risk treatment protocols is important. There are many studies ongoing with the aim of discovering and developing drugs to treat different types of inner ear disorders. The mechanisms of ototoxicity and subsequent loss of hearing function have been mapped in various experimental models and have provided us with useful information for developing protective treatment. When an ototoxic lesion is established, restoration of hearing function becomes more difficult. For both aminoglycoside antibiotics and cisplatin, alarge number of otoprotectors have been suggested. Systemic co-administration of an otoprotector would be the easiest approach to avoid ototoxicity in patients but it may negatively affect the intended pharmacotherapeutic aim of the ototoxic drug. New pharmacological formulations are being developed for local otoprotective treatment. This short review focuses on results from clinical reports on otoprotection in patients treated with aminoglycoside antibiotics and cisplatin. So far there is limited evidence for the safe management of otoprotection in patients. Further high-quality studies are needed to provide reliable data on the safety and effectiveness of pharmacological interventions to reduce drug-induced hearing loss.

Place, publisher, year, edition, pages
SPRINGER, 2019
Keywords
Cisplatin, Aminoglycosides, Hearing loss, Otoprotection, Inner ear
National Category
Otorhinolaryngology
Identifiers
urn:nbn:se:uu:diva-386430 (URN)10.1007/s00106-019-0663-1 (DOI)000469381600007 ()30993373 (PubMedID)
Conference
55th Inner Ear Biology Workshop, SEP 06-08, 2018, Berlin, GERMANY
Available from: 2019-06-25 Created: 2019-06-25 Last updated: 2019-06-25Bibliographically approved
Astradsson, T., Sellberg, F., Berglund, D., Tiblom Ehrsson, Y. & Laurell, G. (2019). Systemic Inflammatory Reaction in Patients With Head and Neck Cancer-An Explorative Study. Frontiers in Oncology, 9, Article ID 1177.
Open this publication in new window or tab >>Systemic Inflammatory Reaction in Patients With Head and Neck Cancer-An Explorative Study
Show others...
2019 (English)In: Frontiers in Oncology, ISSN 2234-943X, E-ISSN 2234-943X, Vol. 9, article id 1177Article in journal (Refereed) Published
Abstract [en]

Aim: To assess the longitudinal pattern of pro-inflammatory cytokines and growth factors in serum up to 1 year following treatment for head and neck cancer. Materials and Methods: Patients with newly diagnosed, curable head and neck cancer were included (n = 30). The most common subsite was oropharynx (n = 13) followed by oral cavity (n = 9). Blood was drawn from all patients at regular intervals (before treatment, 7 weeks after the start of the treatment, and at 3 months and 1 year after termination of treatment) and analyzed for cytokines (Il-1 beta, Il-2, Il-4, Il-5, Il-6, Il-8, Il-10, GM-CSF, TNF-alpha, and IFN-gamma) and growth factors (G-CSF, FGF-2, EGF, and VEGF). Results: The time point of the peak level of pro-inflammatory cytokines was 7 weeks after start of treatment which corresponded for the majority of patients with termination of radiotherapy or chemoradiotherapy. Patients undergoing chemoradiotherapy exhibited a significant increase of IL-1 beta, IL-6, and IL-10 at 7 weeks as compared to pre-treatment levels. At 1 year after termination of treatment four patients experienced recurrence of disease while 26 patients were considered disease-free. The patients with recurrence had significantly higher levels of IL-1 beta, IL-6, IL-8, and IL-10 at 7 weeks after the start of treatment than patients without recurrence. Correlated with T stadium patients with T3-T4 had higher levels of IL-1 beta and IL-8 than patients with T1-T2 7 weeks after the start of treatment. Conclusions: The observed immune response in this explorative study demonstrates that chemoradiotherapy may induce not only a local treatment effect on the immune system but also effects far outside the irradiated field. The result of the study indicates that analysis of a pro-inflammatory panel of cytokines in serum at 7 weeks after the start of treatment could be of prognostic value in patients with head and neck cancer. Further study of a larger cohort could help identify patients at larger risk for recurrent disease with measurements of pro-inflammatory cytokines under and after treatment.

Place, publisher, year, edition, pages
FRONTIERS MEDIA SA, 2019
Keywords
radiotherapy, chemoradiotherapy, cisplatin, cytokines, immune system, growth factors
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-400000 (URN)10.3389/fonc.2019.01177 (DOI)000498540700001 ()31750257 (PubMedID)
Funder
Swedish Cancer Society, 2015/363The Kamprad Family Foundation
Available from: 2019-12-19 Created: 2019-12-19 Last updated: 2019-12-19Bibliographically approved
Kämpfe Nordström, C., Danckwardt-Lillieström, N., Laurell, G., Liu, W. & Rask-Andersen, H. (2019). The Human Endolymphatic Sac and Inner Ear Immunity: Macrophage Interaction and Molecular Expression. Frontiers in Immunology, 9, Article ID 3181.
Open this publication in new window or tab >>The Human Endolymphatic Sac and Inner Ear Immunity: Macrophage Interaction and Molecular Expression
Show others...
2019 (English)In: Frontiers in Immunology, ISSN 1664-3224, E-ISSN 1664-3224, Vol. 9, article id 3181Article in journal (Refereed) Published
Abstract [en]

Background: The endolymphatic sac (ES) is endowed with a multitude of white blood cells that may trap and process antigens that reach the inner ear from nearby infection-prone areas, it thus serves as an immunologic defense organ. The human ES, and unexpectedly the rest of the inner ear, has been recently shown to contain numerous resident macrophages. In this paper, we describe ES macrophages using super-resolution structured fluorescence microscopy (SR-SIM) and speculate on these macrophages' roles in human inner ear defense.

Material and Methods: After ethical permission was obtained, human vestibular aqueducts were collected during trans-labyrinthine surgery for acoustic neuroma removal. Tissues were placed in fixative before being decalcified, rapidly frozen, and cryostat sectioned. Antibodies against IBA1, cytokine fractalkine (CX3CL1), toll-like receptor 4 (TLR4), cluster of differentiation (CD) 68, CD11b, CD4, CD8, and the major histocompatibility complex type II (MHCII) were used for immunohistochemistry.

Results: A large number of IBA1-positive cells with different morphologies were found to reside in the ES; the cells populated surrounding connective tissue and the epithelium. Macrophages interacted with other cells, showed migrant behavior, and expressed immune cell markers, all of which suggest their active role in the innate and adaptive inner ear defense and tolerance.

Discussion: High-resolution immunohistochemistry shows that antigens reaching the ear may be trapped and processed by an immune cell machinery located in the ES. Thereby inflammatory activity may be evaded near the vulnerable inner ear sensory structures. We speculate on the immune defensive link between the ES and the rest of the inner ear.

Keywords
human, cochlea, macrophages, IBA1, structured illumination microscopy
National Category
Otorhinolaryngology Immunology in the medical area
Identifiers
urn:nbn:se:uu:diva-377333 (URN)10.3389/fimmu.2018.03181 (DOI)000457362000001 ()30774637 (PubMedID)
Available from: 2019-02-25 Created: 2019-02-25 Last updated: 2019-02-25Bibliographically approved
Ölander, C., Gudjonsson, O., Kinnefors, A., Laurell, G. & Edfeldt, L. (2018). Complications in translabyrinthine surgery of vestibular schwannoma. Acta Oto-Laryngologica, 138(7), 639-645
Open this publication in new window or tab >>Complications in translabyrinthine surgery of vestibular schwannoma
Show others...
2018 (English)In: Acta Oto-Laryngologica, ISSN 0001-6489, E-ISSN 1651-2251, Vol. 138, no 7, p. 639-645Article in journal (Refereed) Published
Abstract [en]

Objective: To evaluate the risk of complications associated with tumor size and patient's age in translabyrinthine vestibular schwannoma surgery. Methods: 700 patients with vestibular schwannoma primarily underwent translabyrinthine surgery between 1988 and 2014. Pre- and postoperative data were collected in a database and incidence of the postoperative complications cerebrospinal fluid leakage, meningitis, intracranial hemorrhage (ICH), facial nerve function and mortality were assessed and related to the tumor size and patient's age and retrospectively evaluated. Results: The tumor size significantly influenced the incidence of ICH and facial nerve dysfunction whereas age was correlated to facial nerve outcome. Conclusions: The translabyrinthine approach is a safe surgical procedure with relatively low risks of complications. The tumor size was significantly associated with a higher risk of ICH and facial nerve dysfunction whereas age only influenced the facial nerve outcome.

Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD, 2018
Keywords
Translabyrinthine surgery, complications, tumor size, age
National Category
Neurology Otorhinolaryngology
Identifiers
urn:nbn:se:uu:diva-356818 (URN)10.1080/00016489.2018.1427887 (DOI)000432629200008 ()29361875 (PubMedID)
Available from: 2018-08-16 Created: 2018-08-16 Last updated: 2018-08-16Bibliographically approved
Holm, A., Hellman, U., Laurent, C., Laurell, G., Nylander, K. & Olofsson, K. (2018). Hyaluronan in vocal folds and false vocal folds in patients with recurrent respiratory papillomatosis. Acta Oto-Laryngologica, 138(11), 1020-1027
Open this publication in new window or tab >>Hyaluronan in vocal folds and false vocal folds in patients with recurrent respiratory papillomatosis
Show others...
2018 (English)In: Acta Oto-Laryngologica, ISSN 0001-6489, E-ISSN 1651-2251, Vol. 138, no 11, p. 1020-1027Article in journal (Refereed) Published
Abstract [en]

Background: Hyaluronan (HA) is a glycosaminoglycan with viscoelastic properties necessary for vocal fold (VF) vibration and voice production. Changes in HAs molecular mass, possibly related to human papilloma virus, could affect formation/persistence of recurrent respiratory papillomatosis (RRP).

Aims/Objective: Describing mass and localization of HA and localization of HA receptor CD44 in VF and false vocal folds (FVF) in RRP.

Materials and Methods: Biopsies from VF and FVF from 24 RRP patients. Twelve were studied with histo-/immunohistochemistry for HA and CD44 in epithelium, stroma and RRP lesions. Twelve samples were analyzed for HA molecular mass distribution with gas-phase-electrophoretic-molecular-mobility-analyzer (GEMMA).

Results: Three of 23 stains (VF and FVF combined) showed faint HA staining in the epithelium; there was more extensive staining in the stroma. CD44 was present throughout all areas in FVF and VF, it did not concur with HA. GEMMA analysis revealed very high mass HA (vHMHA) with more varying amounts in VF.

Conclusions/Significance: HA was mainly distributed in the stroma. CD44 not binding to HA might explain the non-inflammatory response described in RRP. Possibly crosslinked vHMHA was seen in VF and FVF, with more variable amounts in VF samples. Counteracting HA crosslinking could become a treatment option in RRP.

Keywords
Vocal folds, hyaluronan, CD44, human papilloma virus, recurrent respiratory papillomatosis
National Category
Otorhinolaryngology
Identifiers
urn:nbn:se:uu:diva-378747 (URN)10.1080/00016489.2018.1500712 (DOI)000459000600012 ()30776265 (PubMedID)
Note

背景:透明质酸(HA)是一种糖胺聚糖, 具有声带(VF)振动和发声所必需的粘弹性。HA 分子量的变化可能与人乳头瘤病毒相关, 还可能影响复发性呼吸道乳头状瘤病(RRP)的形成或持续。

目的:描述HA的量和定位, HA受体CD44在VF中的定位和假性声带(FVF)在RRP中的定位。

材料和方法:24名RRP患者的VF和FVF的活组织检查。用组织/免疫组织化学方法研究12个样品的上皮、基质和RRP病变中的HA和CD44。用气-相-电泳 - 分子-迁移率-分析仪(GEMMA)分析另12个样品的HA分子量分布。

结果:23个染色中的3个(VF和FVF组合)在上皮细胞中显示出微弱的HA染色;基质中有更强的染色。 CD44存在于FVF和VF的所有区域, 它与HA不同时存在。 GEMMA分析显示非常高量的HA(vHMHA), 它在VF中的量多变。

结论/意义:HA主要分布在基质中。 CD44不与HA接合可能解释所描述的RRP中的非炎症反应。在VF和FVF中观察到可能交合的vHMHA, 而在VF样品中具有更多的变量。抗HA交合可能成为RRP的治疗选择。

Available from: 2019-03-11 Created: 2019-03-11 Last updated: 2019-03-11Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-7760-246x

Search in DiVA

Show all publications